Back |
home / stock / cvm / cvm message board
Subject | By | Source | When |
---|---|---|---|
Patience and time in a penny stock is | fung_derf | investorshub | 04/14/2023 2:13:53 PM |
Fine with me - gives me more time | drkazmd65 | investorshub | 04/13/2023 3:40:42 PM |
Hey Kids! Its Math time! | sushifishman | investorshub | 04/12/2023 2:17:59 PM |
Chirp Chirp | sushifishman | investorshub | 04/11/2023 11:36:55 PM |
Blame Game | sushifishman | investorshub | 04/10/2023 4:32:52 PM |
Comments to Shareholders. | rdneum | investorshub | 04/10/2023 3:45:41 PM |
Im laughing! | sushifishman | investorshub | 04/10/2023 2:36:35 PM |
When is the peer review article in a | sushifishman | investorshub | 04/08/2023 1:27:37 PM |
Happy Passover Big offering coming in June About $25m | sushifishman | investorshub | 04/06/2023 1:58:11 PM |
How deep to the bottom will this garbage | Master of Puppets | investorshub | 04/04/2023 8:37:12 AM |
April Fools Stinker headed to $1 | sushifishman | investorshub | 04/03/2023 2:37:00 PM |
Nugget Time I have seen the light! | sushifishman | investorshub | 04/01/2023 4:44:29 PM |
News, Short Squeeze, Breakout and More Instantly...
Cel-Sci Corporation Company Name:
CVM Stock Symbol:
NYSE Market:
Dr. Selvaggi was instrumental in the development and approval of lung cancer drugs Zykadia for Novartis and Opdivo for Bristol Myers Squibb CEL-SCI’s Multikine immunotherapy improves the 5-year survival of head and neck cancer patients to 73% compared to 45% in controls and cut...
CEL-SCI Corporation (NYSE American: CVM) today reported financial results for the quarter ended March 31, 2024, as well as key recent clinical and corporate developments. Clinical and Corporate Developments include: In May 2024, CEL-SCI received the go-ahead from the U.S. Food and D...
CEL-SCI Corp (NASDAQ:CVM) shares are trading higher by 18.6% to $1.98 during Wednesday’s session after the company received positive feedback...